The UK and US have agreed to a key trade agreement that will preserve no tariffs on British medicine shipments entering the American market.
Agreement Details of the Pact
As part of the deal, the UK has pledged to boost expenditure on medicines through the public health system. This move secures that duties on these vital products will stay at zero for a period of 36 months.
This development follows recent warnings to dramatically increase tariffs on branded pharmaceutical products, with potential rates floated as high as double the cost.
"This agreement with the Britain bolsters the global environment for cutting-edge drugs and brings much-needed fairness to American-British pharmaceutical trade," a statement said.
Economic Impact
Drugs are one of the the United Kingdom's most significant goods shipped to the United States, which is by far the largest buyer for large companies like GSK and AstraZeneca.
Trade data indicate that in the year leading up to last September, the UK exported drugs valued at £11.1bn to the US. This amount accounted for a significant portion of all goods exports in that timeframe.
"This deal safeguards work, boosts investment and facilitates the UK to become a worldwide center for biotech and pharma," a government official remarked.
Key UK Commitments
The pact involves several notable commitments from the United Kingdom:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it judges new therapies to be too expensive by a quarter.
- Boosted Medicine Funding: There is a aim to double total health service expenditure on drugs from 0.3% of GDP to 0.6% over the next decade.
- Rebate Cap: The amount drug companies must return to the NHS to control costs will be limited at fifteen percent. Last year, rebates exceeded twenty percent.
Recent Tensions
The deal takes place against a ongoing dispute between the pharmaceutical industry and the ministers over drug pricing and approval rates.
The disagreement were exacerbated by arguments that US patients were charged a premium for the equivalent treatments than patients in the UK and Europe.
In recent months, several significant manufacturing plans in the UK have been delayed or abandoned, while multi-billion-dollar funding commitments have been directed toward projects in the United States.
A senior figure stated that the NHS must increase expenditure on medicines, noting that its expenditure on drugs had shrunk as a share of its resources over the previous ten-year period.
